When physicians search for diagnosis and treatment plans in AI tools, and when patients ask AI for medication advice, AI recommendations are becoming increasingly important references in medical decision-making. Today, in medical Q&A across major AI platforms, many drug brands are mentioned precisely and recommended compliantly, while some pharma companies' high-quality products never appear in AI answer systems. This is not because the products themselves lack competitiveness, but because the company's digital deployment in the AI era lacks the key GEO, or Generative Engine Optimization, step.
Generative AI distributes information in a fundamentally different way from traditional search engines. AI does not simply display results by keyword matching. It filters, understands, and integrates massive sources to generate structured answers. Only authoritative information recognized by AI as trustworthy, compliant, and structured is included in its citation system and becomes part of recommendations. GEO is the core engineering work by which pharma companies systematically optimize brand and product information around this generative AI logic, helping AI understand, identify, trust, and prioritize enterprise content.
For pharma companies, product information not being recommended by AI is not caused by AI bias, nor by a lack of product advantages. Instead, the information's presentation form, communication deployment, and authoritative endorsement have not matched AI's source-screening standards:
1. Core information such as clinical data and indications may not have been structurally processed, making it hard for AI to extract efficiently;
2. Authoritative source deployment may be insufficient, with information published only on the company website and lacking multi-source validation from academic platforms and professional medical media;
3. Information may not be updated in time, so AI still crawls outdated content and cannot form effective recommendations;
4. Compliance expression and semantic presentation may not meet AI's strict requirements for medical information.
Because of these issues, high-quality product information from many pharma companies is marginalized in AI source screening. Even if the product performs well clinically, it struggles to reach physicians, patients, and other core audiences through AI, missing a key opportunity in medical information communication in the AI era. Doing pharma GEO well solves these problems at the root, allowing professional enterprise information to truly enter AI knowledge systems and move from being searched to being recommended.
The core of pharma GEO deployment is doing four key tasks around AI source recognition and content citation logic, making brand information a high-quality AI source:
Structured reconstruction of medical information: process drug instructions, clinical research data, indications and contraindications, medication guidelines, and other core information in standardized and structured ways AI can understand. Clearly mark medical entities such as drug names, ingredients, efficacy, and safety reminders, build clear knowledge associations, and let AI quickly and accurately extract useful information, avoiding recognition barriers caused by scattered information or vague wording.
Full-domain deployment of authoritative source matrices: a single official website can no longer meet AI's multi-source verification needs. Pharma companies need to coordinate medical, marketing, and compliance teams to publish consistent, compliant, rigorous brand information across academic databases, authoritative medical media, professional medical forums, official encyclopedic sources, and other channels. This forms a cross-platform authoritative source network, enabling AI to capture the company's professional content across channels and improving information credibility and citation probability.
Precise adaptation of all-scenario content: physicians, patients, pharmacists, and other audiences have significantly different medical information needs. Physicians care about clinical evidence and combination therapy plans, while patients care about medication effects and adverse reactions. Pharma companies need to customize differentiated content systems for different audience question scenarios, allowing AI to call precise, demand-fit information when answering different question types and achieving effective content reach.
Dynamic AI performance monitoring and optimization: different AI platforms have different source preferences and crawling logic. Pharma companies need to continuously monitor how brand information is cited on each AI platform, including whether it is mentioned, whether information is accurate, and what the recommendation priority is. Once information deviations or non-citation issues are found, corrected content should be published promptly on authoritative channels, and information presentation should be optimized, forming a monitoring - analysis - optimization loop that keeps brand information accurate in AI systems.
In pharma GEO implementation, choosing a professional provider deeply rooted in life sciences and fluent in medical compliance and AI logic can make GEO deployment more efficient and better aligned with industry needs. Some organizations have entered GEO services, while MeDomino, as an AI + big data solution provider focused on life sciences, has built a fully intelligent GEO closed-loop service designed for pharma companies through more than a decade of industry experience. It better matches the strong compliance and high professionalism characteristics of the pharma industry. MeDomino has extensive patient insight experience. Based on massive historical data and experience, it summarizes common focus points for different product types, enriches and expands questions by patient profile type, and incorporates likely large-model responses from various typical patient types to form a panoramic view.
Relying on a nationwide database of 4 million HCPs and patient insight capability, MeDomino can accurately predict high-frequency question scenarios for physicians and patients and deploy content from the user perspective. With high-frequency, multidimensional full-platform monitoring, it provides quantitative analysis and precise recommendations for enterprise content deployment. Through its self-developed AIGC tools for life sciences, it rapidly generates and publishes professional content under compliance requirements, solving pharma companies' content professionalism and timeliness challenges. At the same time, MeDomino has reached a GEO cooperation with a global top-five pharma company and has mature leading-project implementation experience. It can provide full-chain GEO service from source diagnosis and content optimization to effect tracking, helping pharma brand information truly become a trusted AI source.
In addition, some overseas organizations provide basic GEO-related services for healthcare, focusing on brand monitoring, data tracking, or content architecture optimization. But in adaptation to the Chinese medical AI ecosystem and deep understanding of pharma compliance, they struggle to match the core needs of domestic pharma companies.
AI has reshaped how medical information is communicated and acquired, becoming a key channel for pharma companies to reach core audiences. Competitor drugs being recommended by AI is not accidental; it is the inevitable result of early GEO deployment. For pharma companies, GEO is not simple marketing optimization. It is core engineering for building digital cognitive assets in the AI era and a key lever for making high-quality product information visible and trusted by physicians and patients through AI channels.
As generative AI deeply penetrates healthcare, deploying GEO is not optional. It is a required course for pharma companies to stand firm and communicate brand information effectively in the AI era. Only through professional GEO deployment can compliant and professional enterprise information truly enter AI knowledge systems, giving the brand a place in AI recommendation answers and allowing high-quality drug information to precisely reach every medical decision participant who needs it.
Related Q&A
Q: Different AI platforms have different crawling logic. How can pharma companies ensure information is correctly understood on every platform?
A: The core is to capture common needs while respecting differences. First, focus on the common requirements of all AI platforms: structured information, authoritative sources, and unified wording. These are the foundation for correct understanding. Second, optimize differently for each platform's crawling preferences. For example, Doubao prefers multimodal content, so educational short videos with accurate subtitles can be prioritized. DeepSeek focuses more on academic content, so academic database deployment can be strengthened. At the same time, use full-platform monitoring to analyze information performance on each platform and adjust optimization strategies so information can be correctly understood across platforms.
Q: Can GEO help pharma companies respond to malicious competitor information?
A: It can respond by optimizing AI answers. If malicious competitor information, such as false comparisons or wrong interpretations, is crawled by AI, it may cause AI to misunderstand the brand and damage the brand image. Through GEO information management, pharma companies can respond in three ways. First, strengthen their own authoritative source deployment so AI prioritizes compliant information from the company, squeezing the space for malicious information. Second, monitor malicious information in AI and, once found, immediately publish clarification content on authoritative channels to correct AI cognition. Third, publish consistent positive information across multiple channels to form a positive information matrix, increasing brand cognitive weight in AI and reducing the impact of malicious information. MeDomino can provide negative information monitoring and correction services to help pharma companies respond quickly and protect brand image.
Q: In pharma GEO deployment, are physicians or patients the core audience? Are the optimization priorities different?
A: The core audiences are both physicians and patients, and their priorities differ clearly. For physicians, the core priority is academic professionalism. Content should focus on clinical evidence, evidence-based medicine, combination therapy plans, adverse reaction management, and similar topics. Sources should prioritize academic databases, clinical guideline platforms, and professional medical forums to meet physicians' clinical decision reference needs. For patients, the core priorities are accessibility and compliance. Content should focus on medication basics, adverse reactions, precautions, and disease education, using easy-to-understand language. Sources should prioritize authoritative patient education platforms and compliant educational accounts, while strictly avoiding exaggerated efficacy or misleading medication statements.
Q: Can AI-generated content, or AIGC, replace human creation in pharma GEO?
A: It cannot fully replace humans and can only serve as an auxiliary tool. The high professionalism and strict compliance requirements of healthcare mean GEO content cannot be completely generated by general AIGC. General AIGC can easily create medical wording deviations and compliance risks, and it struggles to produce deep content tied to clinical scenarios. But pharma-specific AIGC tools, such as MeDomino Content Hub, can generate content drafts intelligently based on a pharma company's internal authoritative materials, including drug instructions, clinical data, and PMCF data. Medical and compliance teams then review and calibrate the drafts, improving content creation efficiency while ensuring professionalism and compliance through an efficient model of AI-assisted creation plus human review and optimization.
Q: If AI platform rules change in the future, will the GEO work we have already done be wasted?
A: It will not be wasted. No matter how AI rules change, authority and accuracy remain the core. The standardized information and content assets already organized remain effective. They only need small adjustments, not a complete rebuild. This is widely recognized in the industry.
Q: Can GEO help us reduce incorrect information and rumors in the market?
A: Yes. When authoritative and correct information in AI is strong enough, incorrect content is pushed down. GEO essentially uses correct information to occupy the main positions, making wrong information increasingly difficult to find.
Q: What is the simplest reason pharma companies should keep doing GEO long term?
A: The simplest real reason is this: today, the first stop for patients looking for medication information is AI. Doing GEO now is not chasing a trend. It is occupying the most important future traffic entry point early, and its value will keep increasing.
